Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | FADS1 | O60427 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4448947 | 1.00 | HPGD (0.54) | HPGDALOX15MAPTMEN1KMT2A | |
| Methane SCHEMBL8701106 | 0.98 | HPGD (0.53) | HPGDALOX15MAPTMEN1KMT2A | |
| SCHEMBL29564585 | 0.85 | HPGD (0.53) | HPGDALOX15MAPTMEN1KMT2A | |
| SCHEMBL14691489 | 0.83 | HPGD (0.55) | HPGDALOX15MAPTMEN1KMT2A | |
| SCHEMBL11206072 | 0.83 | CTSL (0.54) | HPGDALOX15MAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29564409 | 0.83 | HPGD (0.51) | HPGDALOX15MAPTMEN1KMT2A | |
| SCHEMBL8745474 | 0.83 | HPGD (0.55) | HPGDALOX15MAPTMEN1KMT2A | |
| SCHEMBL11206076 | 0.83 | CTSL (0.54) | HPGDALOX15MAPTMEN1KMT2A | |
| SCHEMBL11182616 | 0.82 | MEN1 (0.56) | HPGDALOX15MAPTMEN1KMT2A | |
| SCHEMBL6707517 | 0.82 | ALDH1A1 (0.43) | MAPTMEN1KMT2AALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862837-B2 | Antifouling materials | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2018-01-09 | — | — | US | disclosed |
| US-20160376449-A1 | ANTIFOULING MATERIALS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-12-29 | — | — | US | disclosed |
| US-20090023661-A1 | Use of Antagonists of the Bradykinin B2 Receptor for the Treatment of Osteoarthrosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20040248809-A1 | Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248809-A1 | Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis | BDKRB2, BDKRB1, PLAT | HPGD 132/4885ALOX15 1932/4885MAPT 3179/4885 |
| US-20160376449-A1 | ANTIFOULING MATERIALS | PFAS, FLNB, FLNA | HPGD 3634/4885ALOX15 1153/4885MAPT 4276/4885 |
| US-20090023661-A1 | Use of Antagonists of the Bradykinin B2 Receptor for the Treatment of Osteoarthrosis | BDKRB2, BDKRB1, PLAT | HPGD 140/4885ALOX15 1920/4885MAPT 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.